Business
Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma
Unlocks path towards registrational Phase 3 trial planned to start in 2026 Data from Phase 2 SCOPE trial show iSCIB1+ has potential to redefine standard of care (SoC) iSCIB1+ shows an interim 24%-point improvement in progression free survival (PFS) over real world SoC and historic controls NOTTINGHAM, United Kingdom, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of active immunotherapies to treat cancer, announces the U.S. Food and Drug Administration (FDA) h
About this update from Scancell Holdings Plc
[{"type":"image","alt":"Scancell Holdings Plc","displaySize":"","headline":null,"caption":"Scancell Holdings Plc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":54,"url":"https://media.zenfs.com/en/globenewswire.com/b13bc6685f23fb28f74542b8ae6c6fee"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FhJvhpDXvP8ngfWe1NUy2w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc2O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/b13bc6685f23fb28f74542b8ae6c6fee","width":300,"height":54}},"lazy":false},{"type":"text","content":"Unlocks path towards registrational Phase 3 trial planned to start in 2026","length":74,"tagName":"p"},{"type":"text","content":"Data from Phase 2 SCOPE trial show iSCIB1+ has potential to redefine standard of care (SoC)","length":91,"tagName":"p"},{"type":"text","content":"iSCIB1+ shows an interim 24%-point improvement in progression free survival (PFS) over real world SoC and historic controls","length":123,"tagName":"p"},{"type":"text","content":"NOTTINGHAM, United Kingdom, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of active immunotherapies to treat cancer, announces the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a registrational Phase 3 trial of its iSCIB1+ Immunobody® in advanced melanoma, with progression free survival as the agreed surrogate endpoint.","length":415,"tagName":"p"},{"type":"text","content":"Scancell has completed the 140-patient SCOPE Phase 2, open-label, multi-centre study evaluating ImmunoBody® immunotherapies (SCIB1 and iSCIB1+) in combination with nivolumab plus ipilimumab in previously untreated unresectable stage IIIB/IV melanoma. In addition to demonstrating potentially best-in-class efficacy and durability, from the data analysis we have identified a selection marker to enrich the phase 3 trial for responders.","length":435,"tagName":"p"},{"type":"text","content":"Dr Phil L'Huillier, CEO of Scancell, said: "This IND clearance creates a clear pathway for late-stage registrational development of our iSCIB1+ Immunobody®. Data from the Phase 2 SCOPE trial shows a significant improvement in progression free survival as well as emerging overall survival with iSCIB1+ compared to historic benchmarks. I take this endorsement of our program as a strong measure of the clinica...